A dataset quantifying polypharmacy in the United States

Abstract

Polypharmacy is increasingly common in the United States, and contributes to the substantial burden of drug-related morbidity. Yet real-world polypharmacy patterns remain poorly characterized. We have counted the incidence of multi-drug combinations observed in four billion patient-months of outpatient prescription drug claims from 2007–2014 in the Truven Health MarketScan® Databases. Prescriptions are grouped into discrete windows of concomitant drug exposure, which are used to count exposure incidences for combinations of up to five drug ingredients or ATC drug classes. Among patients taking any prescription drug, half are exposed to two or more drugs, and 5% are exposed to 8 or more. The most common multi-drug combinations treat manifestations of metabolic syndrome. Patients are exposed to unique drug combinations in 10% of all exposure windows. Our analysis of multi-drug exposure incidences provides a detailed summary of polypharmacy in a large US cohort, which can prioritize common drug combinations for future safety and efficacy studies.

Motoric Cognitive Risk Syndrome in Polypharmacy

“…The overall prevalence of polypharmacy in this large community‐based US sample was 37%, similar to what was described elsewhere . The prevalence of MCR of 7.2% in this sample of participants 65 years and older was lower than a pooled multi‐country sample that reported a prevalence of 9.7% in participants 60 years and older .…”

The effect of artichoke on lipid profile: A review of possible mechanisms of action

“…For instance, the intake of multiple medicines, i.e. the polypharmacy, is relatively common in older populations, which in a daily basis could vary between five to ten different types of medicines [76,77]. Adherence to polypharmacy is already very difficult per se; adding ALE capsules may further disturb the prescribed dyslipidaemia therapy due to the large amount of capsules involved [78].…”

The FDA-approved drugs ticlopidine, sertaconazole, and dexlansoprazole can cause morphological changes inC. elegans

“…About 4.4 million people in the United States are estimated to have been prescribed ticlopidine, sertaconazole, or dexlansoprazole in a 7-year period (estimate based on those insured between 2007 and 2014 [25]). Ticlopidine is thought to inhibit platelet aggregation by blocking an adenosine-diphosphate receptor [26] and is sometimes used during the placement of stents in coronary arteries.…”